By PR Newswire | Article Rating: |
|
February 12, 2014 06:30 AM EST | Reads: |
216 |

ANAHEIM, Calif., Feb. 12, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release fourth quarter and full year 2013 financial results on Tuesday, February 25, 2014 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, February 25, 2014 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and corporate developments.
The call can be accessed in the following ways:
- By webcast: At Questcor's investor relations website, http://ir.questcor.com/.
- By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
- By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call. The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 55826448.
About Questcor
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. For more information about Questcor, please visit www.questcor.com.
SOURCE Questcor Pharmaceuticals, Inc.
Published February 12, 2014 Reads 216
Copyright © 2014 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Apr. 24, 2018 05:15 AM EDT Reads: 1,520 |
By Elizabeth White Apr. 24, 2018 04:30 AM EDT Reads: 2,671 |
By Elizabeth White ![]() Apr. 24, 2018 03:15 AM EDT Reads: 5,486 |
By Pat Romanski ![]() Apr. 24, 2018 01:15 AM EDT Reads: 16,169 |
By SmartBear Blog ![]() Apr. 24, 2018 01:00 AM EDT Reads: 2,017 |
By Yeshim Deniz Apr. 24, 2018 01:00 AM EDT Reads: 2,443 |
By Liz McMillan ![]() Apr. 24, 2018 12:00 AM EDT Reads: 8,121 |
By Pat Romanski ![]() Apr. 23, 2018 11:30 PM EDT Reads: 1,994 |
By Pat Romanski Apr. 23, 2018 11:15 PM EDT Reads: 2,826 |
By Elizabeth White ![]() Apr. 23, 2018 11:00 PM EDT Reads: 1,167 |
By Elizabeth White ![]() Apr. 23, 2018 11:00 PM EDT Reads: 6,438 |
By Liz McMillan ![]() Apr. 23, 2018 10:45 PM EDT Reads: 7,017 |
By Pat Romanski ![]() Apr. 23, 2018 10:45 PM EDT Reads: 7,206 |
By Liz McMillan ![]() Apr. 23, 2018 10:30 PM EDT Reads: 17,455 |
By Yeshim Deniz ![]() Apr. 23, 2018 09:45 PM EDT Reads: 6,871 |